| Primary |
| Hepatitis B |
51.9% |
| Hepatic Cirrhosis |
14.9% |
| Product Used For Unknown Indication |
8.2% |
| Drug Use For Unknown Indication |
5.2% |
| Chronic Hepatitis B |
3.9% |
| Gastritis |
1.9% |
| Hiv Infection |
1.8% |
| Hypertension |
1.8% |
| Osteoporosis |
1.5% |
| Amyotrophic Lateral Sclerosis |
1.4% |
| Constipation |
1.2% |
| Chronic Hepatitis |
1.1% |
| Hepatitis B Virus |
1.0% |
| Hepatitis B Virus Test |
0.8% |
| Gastric Ulcer |
0.7% |
| Insomnia |
0.6% |
| Immunosuppression |
0.5% |
| Antiviral Treatment |
0.5% |
| Depression |
0.5% |
| Hypothyroidism |
0.5% |
|
| Hepatic Neoplasm Malignant |
11.6% |
| Osteomalacia |
11.3% |
| Renal Impairment |
9.8% |
| Renal Tubular Disorder |
8.0% |
| Renal Failure |
7.0% |
| Viral Load Increased |
6.7% |
| Viral Mutation Identified |
4.3% |
| Tubulointerstitial Nephritis |
4.0% |
| Thrombocytopenia |
3.7% |
| Alanine Aminotransferase Increased |
3.4% |
| Fanconi Syndrome Acquired |
3.4% |
| Hepatitis B |
3.4% |
| Weight Decreased |
3.4% |
| Drug Ineffective |
3.1% |
| Hepatitis |
3.1% |
| Liver Disorder |
3.1% |
| Hypophosphataemia |
2.8% |
| Platelet Count Decreased |
2.8% |
| Rash |
2.8% |
| Renal Disorder |
2.8% |
|
| Secondary |
| Hepatitis B |
39.5% |
| Hepatic Cirrhosis |
18.7% |
| Drug Use For Unknown Indication |
11.4% |
| Product Used For Unknown Indication |
6.6% |
| Hiv Infection |
4.8% |
| Chronic Hepatitis B |
3.3% |
| Osteoporosis |
2.8% |
| Gastritis |
2.8% |
| Hypertension |
2.2% |
| Amyotrophic Lateral Sclerosis |
1.3% |
| Constipation |
1.3% |
| Ascites |
1.1% |
| Hepatitis B Virus Test |
0.8% |
| Gastric Ulcer |
0.6% |
| Gastroenteritis |
0.6% |
| Renal Failure |
0.6% |
| Antifungal Prophylaxis |
0.4% |
| Atrial Fibrillation |
0.4% |
| Liver Disorder |
0.4% |
| Pain |
0.4% |
|
| Hepatic Neoplasm Malignant |
14.6% |
| Renal Failure |
9.4% |
| Renal Tubular Disorder |
7.5% |
| Osteomalacia |
7.0% |
| Renal Impairment |
6.6% |
| Tubulointerstitial Nephritis |
5.6% |
| Weight Decreased |
5.6% |
| Viral Load Increased |
4.7% |
| Blood Creatinine Increased |
4.2% |
| Fanconi Syndrome |
4.2% |
| Urticaria |
3.8% |
| Vomiting |
3.8% |
| Renal Disorder |
3.3% |
| Hepatic Failure |
2.8% |
| Liver Disorder |
2.8% |
| Multiple Fractures |
2.8% |
| No Therapeutic Response |
2.8% |
| Pneumocystis Jiroveci Pneumonia |
2.8% |
| Spinal Compression Fracture |
2.8% |
| Stevens-johnson Syndrome |
2.8% |
|
| Concomitant |
| Hepatitis B |
21.3% |
| Product Used For Unknown Indication |
12.0% |
| Hepatic Cirrhosis |
11.4% |
| Hepatic Neoplasm Malignant |
10.6% |
| Drug Use For Unknown Indication |
6.7% |
| Diabetes Mellitus |
6.1% |
| Prophylaxis |
3.9% |
| Hypertension |
3.6% |
| Liver Transplant |
3.6% |
| Aplastic Anaemia |
3.4% |
| Constipation |
2.5% |
| Hiv Infection |
2.2% |
| B-cell Lymphoma |
1.9% |
| Gastrointestinal Disorder |
1.9% |
| Hepatitis C |
1.9% |
| Gastritis |
1.7% |
| Iron Overload |
1.6% |
| Hyperammonaemia |
1.4% |
| Immunosuppression |
1.4% |
| Dyspepsia |
1.2% |
|
| Rash |
10.5% |
| Renal Impairment |
9.5% |
| Weight Decreased |
8.4% |
| Hepatic Function Abnormal |
6.3% |
| Vomiting |
6.3% |
| Osteoporosis |
5.3% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
5.3% |
| Viral Load Increased |
5.3% |
| Hepatic Failure |
4.2% |
| Hepatitis B |
4.2% |
| Platelet Count Decreased |
4.2% |
| Sepsis |
4.2% |
| Syncope |
4.2% |
| Chemical Peritonitis |
3.2% |
| Hepatic Neoplasm Malignant |
3.2% |
| Hepatitis B Dna Increased |
3.2% |
| Loss Of Consciousness |
3.2% |
| Oesophageal Varices Haemorrhage |
3.2% |
| Pancytopenia |
3.2% |
| Rectal Cancer |
3.2% |
|
